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Abstract: Many studies have shown the role of myeloperoxidase (MPO) in leukemogenic activity of etoposide. The aim 
of our study was to determine whether inhibition of MPO activity has influence on the formation of double-stranded 
DNA breaks (DSBs) that may contribute to the characteristic of leukemia translocations. Studies were carried out on 
HL-60 cell line, which were preincubated with the MPO inhibitor 4-aminobenzoic acid hydrazide (ABAH), or antioxi-
dant N-acetyl-L-cysteine (NAC), followed by incubation at different concentrations of etoposide (1–10 mM) for 4 hours. 
Cytotoxicity was investigated using propidium iodide staining. Marker of DSBs, a phosphorylated form of histone 2AX 
(gH2AX) was detected using immunocytochemical methods. Cells were analyzed by flow cytometry. ABAH significantly 
reduced the cytotoxicity and the gH2AX level induced by lower concentrations of etoposide (1 and 1.5 mM) and did not 
modify the action of higher concentration (10 mM) of this cytostatic drug. NAC exerted similar impact as ABAH on the 
level of gH2AX induced by etoposide. The results of this study suggest that MPO contributes to increase of the DSBs level 
induced by low concentrations of etoposide in myeloid cells.
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Introduction
Double-stranded DNA breaks (DSBs) are considered the most lethal damage of nucleic 
acid. Unrepaired breaks lead to apoptosis and chromosomal aberration and contribute to 
neoplastic transformation. Their role in carcinogenesis indicates drug-dependent tumors 
occurring after the treatment with DNA damaging agents, which induce DSBs [1, 2]. This 
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damage can also arise under the influence of reactive oxygen species (ROS), whose lev-
el is often elevated in certain cancers, including myeloid malignancies [3]. Mutations in 
proto-oncogenes and fused genes characteristic of leukemias contribute to the overpro-
duction of ROS. In turn, ROS can directly lead to the formation of DSBs [3, 4]. It was ob-
served that acute myeloid leukemia (AML) cells with a mutation of the FMS-like tyrosine 
kinase-3/internal tandem duplication (FLT3/ITD), characteristic of aggressive forms of the 
disease, produce more ROS and DSBs [4]. In addition, blocking FLT3 using inhibitor CEP-701 
led to decreased level of DSBs, which was detected with the marker of this damage, phos-
phorylated histone 2AX (gH2AX).
In a very short time after the formation of DSBs, H2AX is phosphorylated by the ataxia 
teleangiectasia mutated (ATM) kinase and accumulates at the site of DNA damage. Phos-
phorylated H2AX takes part in response to DNA damage, inter alia by activating DNA 
repair proteins [5, 6].
DSBs are repaired in two ways: homologous recombination (HR) and nonhomologous 
end joining (NHEJ) [3, 7]. NHEJ repair takes place in all cell cycle phases and is often used 
to repair DSBs [8]. The process of NHEJ connecting broken DNA ends with a very low 
homology is not always precise and often leads to small DNA deletions [9, 10], which can 
cause chromosomal translocations, so very obvious for leukemias. Studies have shown that 
these translocations occur during the repair of DSBs in the NHEJ or in variable, diverse and 
joining V(D)J recombination [11–13]. 
One of the chemotherapeutic agents which induce DSBs in cancer cells and in normal 
proliferating cells is etoposide [14]. Etoposide is widely used in the treatment of certain solid 
tumors, leukemias and lymphomas [15]. The most common side effect caused by this drug 
is myelosuppression [16, 17]. Etoposide can also induce treatment-related acute myeloid leu-
kemia (t-AML) in a few percent of patients [18]. DSBs that arise after etoposide treatment 
may be not only due to the stabilization of the topoisomerase II–DNA cleavable complex but 
also due to its radicals produced in myeloid precursors under the influence of myeloperox-
idase (MPO) [14, 19]. It was also shown that the appearance of translocation of mixed-lin-
eage leukemia (MLL) gene, a mutation characteristic of t-AML, correlates with the level of 
etoposide phenoxyl radicals in myeloid progenitor cells expressing the CD34 antigen [20].
Etoposide can also induce oxidative damage to DNA and single strand breaks (SSBs) that 
interfere with the activity of DNA topoisomerase II in MPO-rich cells [21, 22]. Examining 
the role of MPO in the formation of DSBs under the influence of etoposide can contribute 
to the understanding of the leukemogenic activity of etoposide. The aim of our study was to 
verify the hypothesis whether the inhibition of MPO activity can influence the DSBs caused 
by etoposide in cells of myeloid lineage.
Materials and methods
HL-60 Cell culture
HL-60 cell line was purchased from Europea Branch of ATCC (American Type Cell Culture, 
UK). The cells were grown in RPMI 1640 medium (ATCC, UK) supplemented with 10% 
fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA), without antibiotics at 37°C 
Monika A. Papież, Wirginia Krzyściak et al.
45
in a 5% CO2 and 95% humidified atmosphere. The cells in the logarithmic growth phase 
were seeded in 24-well culture plates at a density of 0.4 × 106 cells/well. 
Treatment of HL-60 cells
In order to determine the role of MPO in cytogenotoxicity of etoposide, the cells (0.4 × 106 cells/ 
well) were preincubated with 100 mM specific inhibitor of MPO 4-aminobenzoic acid hy-
drazide (ABAH) for 24 hours followed by incubation in the presence of different concen-
trations of etoposide (1–10 mM) for the next 4 hours. We used 100 mM ABAH because 
further increasing the concentration of this inhibitor did not inhibit more of MPO activity 
(data not shown). ABAH and etoposide were dissolved in dimethyl sulfoxide (DMSO) and 
subsequently diluted in phosphate buffered saline (PBS). Final concentration of DMSO did 
not exceed 0.3% in the culture medium. Reagents were purchased from Sigma-Aldrich, 
St. Louis, Missouri, USA. Control cells were incubated in the presence of DMSO only. The 
experiment was repeated three times.
Evaluation of cytotoxicity and detection of gH2AX
To determine the cytotoxicity, HL-60 cells after the treatment were washed twice in PBS (230 × g) 
for 5 minutes. The cells were resuspended in 100 μL of PBS and 10 μL of propidium iodide 
(PI, Sigma-Aldrich, St. Louis, MO, USA) staining solution (10 μg/mL) was added. The cells 
were incubated for 1 minute in the dark. Next, 300 μL of PBS was added and the cells were 
immediately analyzed by flow cytometry. 
For the detection of DSB, phosphorylated H2AX (gH2AX) at serine 139 (Santa Cruz 
Biotechnology, Inc. Dallas, Texas, USA) was detected as a marker [23, 24]. The cells were 
fixed on ice with 1% methanol-free formaldehyde solution in PBS for 15 minutes and 
permeabilized with ice-cold 70% ethanol in deionized water for 24 hours. After washing, 
the cells (0.4 × 106) were stained with primary rabbit monoclonal anti-gH2AX (Ser 139) 
antibody dissolved in Bovine serum albumin — Triton X 100 — PBS medium (BSA-T-
PBS, Sigma–Aldrich Co. St. Louis, MO, USA) for 2 hours at room temperature. Next, 
they were washed with BSA-T-PBS (300 × g, 5 minutes) and incubated with the second-
ary anti-rabbit IgG (H+L) F(ab¢)2 fragment of goat antibody conjugated with Alexa Fluor 
647 (Santa Cruz Biotechnology, Inc. Dallas, Texas, USA), diluted in BSA-T-PBS for 30 
minutes at room temperature in the dark. An isotype control was the rabbit monoclonal 
IgG XP antibody (Santa Cruz Biotechnology, Inc. Dallas, Texas, USA). DNA was stained 
with 5 μg/mL PI and 0.1% RNAse A (Sigma–Aldrich Co. St. Louis, MO, USA) in PBS 
for 30 minutes at room temperature in dark. Red and blue lasers were used for the anal-
ysis of the cells, using 633 nm excitation for Alexa Fluor 647 (660/20 BP filter) and 488 
nm excitation for PI/PE (575/26 BP filter). Cell doublets and debris were excluded from 
analysis using PI width versus PI area. Analysis was performed on at least 20.000 single 
cells.
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Cytochemical detection of MPO activity
MPO activity was detected using 4-chloro-1-naphthol kit (Merck KgaA, Darmstadt, Ger-
many) according to manufacturer’s instruction. The cytochemical reaction is based on the 
oxidation of 4-chloro-1-naphthol which is converted to a black brownish insoluble dye. The 
intensity of staining is proportional to MPO activity.
Statistical analysis
One-way ANOVA and the Newman–Keuls post-hoc test were used to calculate the statistical 
significance between groups. In the absence of the homogeneity of variance, the non-para-
metric Kruskal–Wallis test was used. All data are shown as mean ± SEM.
Results
MPO inhibitor reduced the cytogenotoxic effects induced by low concentrations  
of etoposide
Etoposide increased significantly the number of dead cells compared to controls, depend-
ing on the concentration used (Fig. 1). An inverse relationship was observed in the case of 
gH2AX fluorescence intensity. Greater increase in gH2AX fluorescence was observed un-
der the influence of lower concentrations of etoposide (1 and 2 mM), than when 10 mM of 
the cytostatic drug was used (Fig. 2, 3). Given that apoptosis is preceded by DNA damage, 
this effect is likely due to apoptosis of the cells after 4 hours of incubation with 10 mM of 
etoposide compared to the low concentrations (1–2 mM), where DNA damage just started 
to happen.
Preincubation with ABAH followed by incubation with etoposide led to significant 
reduction of the proportion of death cells treated with low concentrations of etoposide 
(1 or 1.5 mM) compared to etoposide alone (Fig. 1). However, more death cells were signifi-
cantly observed after treatment with ABAH and etoposide (1 or 1.5 mM) compared to the 
control. ABAH did not reduce the cytotoxic effects of etoposide at highest concentration 
(10 mM) (Fig. 1). 
Preincubation with ABAH followed by treatment with 1 mM of etoposide significantly 
decreased the fluorescence intensity of gH2AX compared to etoposide alone (Fig. 2, 4). 
However, the level of H2AX phosphorylation was statistically significant and higher after 
treatment with ABAH plus 1 mM of etoposide in comparison to the control. Treatment with 
ABAH and 2 mM of etoposide led to an insignificant but a clear reduction in the fluorescence 
intensity of gH2AX compared to the cytotoxic drug alone. ABAH did not modify signifi-
cantly the level of H2AX phosphorylation induced by etoposide at a concentration of 10 mM, 
although there was an increase in the intensity of gH2AX fluorescence after treatment with 
ABAH and etoposide (Fig. 2). 
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Fig. 1. The cytotoxicity induced by etoposide in HL-60 cells with normal or decreased activity of MPO. 
The cells were pretreated or not with 100 μM ABAH for 24 hours followed by incubation with etoposide. 
Cytotoxicity was analyzed by flow cytometry. (A) Precentage of death cells. Data are presented as mean ± S.D. 
of the mean. Eto — etoposide, *p <0.05, **p <0.01 vs. control, ##p <0.01 vs. Eto. (B) Cytochemical detection 
of MPO activity in control and ABAH-treated HL-60 cells. × 400.
Fig. 2. The influence of etoposide on phosphorylation of H2AX in HL-60 cells with normal or decreased 
activity of MPO. The cells were pretreated or not with 100 μM ABAH for 24 hours followed by incubation 
with etoposide. Fluorescence of gH2AX was analyzed by flow cytometry. Data are presented as mean ± S.D. 
of the mean. Eto — etoposide, *p <0.05, **p <0.01, ***p <0.001 vs. control, #p <0.05 vs. Eto.
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Fig. 3. The influence of free radicals on etoposide induced phosphorylation of H2AX in HL-60 cells. The 
cells were pretreated or not with 6 mM NAC for 1 hour followed by incubation with etoposide. Fluorescence 
of gH2AX was analyzed by flow cytometry. Data are presented as mean ± S.D. of the mean. Eto — etoposide, 
*p <0.05, **p < 0.01, ***p <0.001 vs. control, #p <0.05 vs. Eto.
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Fig. 4. Representative contour plots of gH2AX and DNA staining of HL-60 cells. Eto — etoposide. gH2AX 
is located within rhomboid gates.
Antioxidant NAC protects HL-60 cells against etoposide-induced phosphorylation  
of H2AX
To confirm that etoposide prooxidative action leads to increased phosphorylation of H2AX, 
we performed preincubation of HL-60 cells with NAC followed by incubation with etoposide. 
As in the case of treatment with ABAH, preincubation with NAC significantly decreased 
the level of gH2AX induced by 1 mM of etoposide compared to the cytostatic drug alone 
(Fig. 3, 4). After treatment with NAC followed by 2 mM of etoposide, the level of gH2AX 
decreased but not to a significant level compared to the cytostatic drug alone. However, 
NAC did not significantly modify the impact of 10 mM etoposide on the level of H2AX 
phosphorylation (Fig. 3).
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Discussion
There is increasing evidence for the role of MPO in inducing the carcinogenic effect of 
etoposide [20, 25]. Etoposide induces myeloid leukemia or myelodysplastic syndromes and 
does not lead to the development of other types of white blood malignancies [16]. Etoposide 
and its metabolites catechols are subjected to a one-electron oxidation by MPO to much 
less genotoxic radicals [19], as has been identified by electron paramagnetic resonance [25].
Our results indicate that inhibition of MPO activity decreases the lethal and mutagenic 
DSBs induced by the low concentrations of etoposide in HL-60 cells. MPO may, therefore, 
increase the cytogenotoxic effect of lower concentrations of this cytostatic drug. Our study 
is probably the first to point out the correlation between the role of inhibition of MPO activ-
ity in reducing the level of the DSB and the concentration of etoposide. It should be added 
that the risk of t-AML increases with increasing frequency of etoposide use or length of 
use [26]. 
The formation of DSBs after the treatment of HL-60 cells with a low concentration of 
etoposide (1 mM) is much more dependent on the prooxidative action of this cytostatic 
drug compared to a higher dose. ABAH limited H2AX phosphorylation induced by 1 mM 
of etoposide by about 30%, while NAC by about 60%. It is worth noting that NAC decreased 
etoposide-indued phosphorylation of H2AX to an insignificant level compared to the control.
However, after incubation with ABAH and 1 mM of etoposide, a significantly higher level 
of gH2AX was observed compared to the control. This effect could be due to the incomplete 
inhibition of MPO through ABAH [27]. Moreover, although MPO is a major enzyme that 
metabolizes etoposide in myeloid cells, because the level of expression of cytochrome P450 
is much lower in these cells, the fact that prostaglandin synthetase is also involved in the 
formation of etoposide radicals [19] cannot be ruled out.
Our research shows that the higher the concentration of etoposide, the lesser the role 
of MPO in the induction of DSBs. Formation of DSBs induced by 10 mM of etoposide in 
myeloid cells is caused most likely through direct interaction with a complex of DNA–to-
poisomerase II. Indirectly, it can be concluded that the participation of MPO in genotoxic 
action at a low concentration of etoposide correlated with the induction of cytotoxicity. 
ABAH restricted the cytotoxic effects of etoposide at low concentrations (1 and 1.5 mM) but 
not at high concentration. It should be added that etoposide was detected at a concentration 
of 0.2–150 mM [16, 28–32] in the serum of patients with AML.
Etoposide can be a source of radicals damaging macromolecules not only DNA but also 
proteins, including DNA repair proteins, leading to various kinds of damage such as DSBs, 
increasing the likelihood of translocation and mutagenesis in myeloid cells with highly ac-
tive MPO. The obtained results indicate the role of inhibition of MPO activity in reducing 
the most lethal and mutagenic DNA lesions caused by low concentration of etoposide in 
myeloid cells.
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